Inclusion criteria:

          -  Participants must be ≥ 12 years of age inclusive, at the time of signing the informed
             consent

          -  Disease location amenable to tumor biopsy at baseline

          -  Measurable disease

          -  For Cohort A1 (classic Hodgkin's lymphoma [cHL] anti-programmed cell death protein
             1/ligand 1 [PD-1/PD-L1] inhibitor naïve): Histologically confirmed advanced cHL that
             has relapsed or progressed after at least 3 lines of systemic therapy that may include
             autologous hematopoietic stem cell transplant (auto-HSCT) or auto-HSCT and brentuximab
             vedotin (BV)

          -  For Cohort A2 (cHL anti-PD-1/PD-L1 inhibitor progressor): Histologically confirmed
             advanced cHL which has relapsed or progressed after one previous anti-PD-1/PD-L1
             containing regimen as the most recent prior therapy but no more than 4 lines of
             previous chemotherapy including the anti-PD-1/PD-L1 containing regimen and
             documentation of benefit during or after the anti-PD-1/PD-L1 containing regimen within
             4 months prior to initiation of investigational medicinal product (IMP)

          -  For Cohort B (diffuse large B-cell lymphoma [DLBCL]): Histologically confirmed
             advanced DLBCL that has relapsed or progressed after 2 lines of systemic therapy
             including auto-HSCT or 2 lines of systemic therapy for participants who are not
             eligible for auto-HSCT

          -  For Cohort C (peripheral T-cell lymphoma [PTCL]): Histologically confirmed advanced
             PTCL that has relapsed or progressed after either first-line chemotherapy and
             auto-HSCT as consolidation of first remission or first-line chemotherapy if
             participants are ineligible for auto-HSCT

          -  Body weight of > 45 kg for patients with age <18 years

        Exclusion criteria:

          -  Prior exposure to agent that blocks CD38

          -  For patients with cHL (PD-1/PD-L1 naïve), DLBCL or PTCL prior exposure to any agent
             (approved or investigational) that blocks the PD-1/PD-L1, PD-L2, CD137, CTLA-4 or
             LAG-3

          -  Evidence of other immune related disease/conditions

          -  Has received a live-virus vaccination within 28 days of planned treatment start;
             seasonal flu vaccines that do not contain live virus are permitted

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2

          -  Poor bone marrow reserve

          -  Poor organ function

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.